Myrislignan
Based on 1 publication(s) in Google Scholar
Myrislignan is a PI3K/AKT/NF-κB inhibitor that can cross the blood-brain barrier. Myrislignan exerts anticancer activity by inducing apoptosis and ferroptosis. Myrislignan inhibits the replication and invasion of Toxoplasma gondii; it induces reactive oxygen species (ROS) imbalance, autophagy, and the death of Toxoplasma gondii tachyzoites. Myrislignan inhibits mitochondrial function and ERK1/2 phosphorylation to improve ovariectomy-induced osteoporosis. Myrislignan can be used in studies related to gastric cancer, glioblastoma, osteoporosis, and toxoplasmosis.
For research use only. We do not sell to patients.
- Purity : 99.53%
- CAS No.: 171485-39-5
- Formula: C21H26O6
- Molecular Weight:374.43
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications Citing Use of MedChemExpress (MCE) Myrislignan
More
Biological Activity
Description
In Vitro
Myrislignan (50-200 μM; 48-72 h) inhibits the viability of human gastric cancer SGC-7901 cells in a dose-dependent manner[1].
Myrislignan (50-200 μM; 48 h) promotes apoptosis of human gastric cancer SGC-7901 cells in a dose-dependent manner[1].
Myrislignan (50-200 μM; 48 h) downregulates the protein expression of PI3K and AKT in a dose-dependent manner in human gastric cancer SGC-7901 cells in vitro, and upregulates the protein expression of BAX, Caspase-3 and Caspase-9[1].
Myrislignan (5-60 μg/mL; 24-48 h) inhibits the growth of human glioblastoma cell lines U87 and U251, as well as human low-grade glioma cell lines SHG44, HS683, and SW1088 in a dose- and time-dependent manner, while a low dose (30 μg/mL) shows no toxicity to the human normal astrocyte cell line NHA[2].
Myrislignan (5-30 μg/mL; 24 h) inhibits the migration and invasion abilities of human glioblastoma cell lines U87 and U251 in a dose-dependent manner[2].
Myrislignan (5-30 μg/mL; 48 h) dose-dependently impairs the wound healing capacity of human glioblastoma cell lines U87 and U251[2].
Myrislignan (5-30 μg/mL) dose-dependently regulates the expression of EMT-related proteins in human glioblastoma cell lines U87 and U251, and inhibits the activation of the NF-κB pathway by reducing the levels of p-p65 and p-IκB-α[2].
Myrislignan (5-30 μg/mL; 48 h) dose-dependently inhibits the activity of the NF-κB signaling pathway in human glioblastoma cell lines U87 and U251[2].
Myrislignan (15 μg/mL) reduces the levels of nuclear and total phosphorylated p65 in the human glioblastoma cell line U87 without altering the total p65 level[2].
Myrislignan (10 μg/mL) induces growth inhibition of the human glioma cell line U87 via ferroptosis. This effect is reversed by the ferroptosis inhibitor Fer-1 (HY-100579) and enhanced by the GPX4 inhibitor RSL3 (HY-100218A)[2].
Myrislignan (5-15 μg/mL) dose-dependently induces lipid peroxidation and reduces the levels of antioxidant molecules without affecting the labile iron pool in the human glioblastoma cell line U87[2].
Myrislignan (5-15 μg/mL) induces dose-dependent ultrastructural changes of mitochondria associated with ferroptosis in the human glioblastoma cell line U87[2].
Myrislignan (5-15 μg/mL) downregulates the protein level of SLC7A11 in the human glioblastoma cell line U87 in a dose-dependent manner, without altering the expression levels of Nrf2, TFR1 or GPX4[2].
Myrislignan (0-80 μM; 48-96 h) exerts no effect on the viability of primary mouse bone marrow macrophages and does not induce their apoptosis even at concentrations up to 80 μM and treatment durations as long as 96 h[3].
Myrislignan (0-30 μM; 7 days) inhibits RANKL-induced osteoclast differentiation of primary mouse bone marrow macrophages in a dose-dependent manner, and its inhibitory effect peaks at the middle stage of differentiation (days 3-4) at a concentration of 30 μM[3].
Myrislignan (15-30 μM; 7 days) inhibits the formation of podosome belts-a key cytoskeletal feature of mature osteoclasts-in primary mouse bone marrow macrophages treated with RANKL for 7 days[3].
Myrislignan (15-30 μM; 2 days) impairs the bone resorption function of mature osteoclasts derived from primary mouse bone marrow macrophages[3].
Myrislignan (15-30 μM; 7 days) dose-dependently inhibits the expression of osteoclast-specific genes in RANKL-treated primary mouse bone marrow macrophages[3].
Myrislignan (15-30 μM; 3-7 days) inhibits mitochondrial function in primary mouse bone marrow macrophages treated with RANKL, reduces mtROS production on day 3, and decreases mitochondrial membrane potential on day 7[3].
Myrislignan (30 μM; 60 min) specifically inhibits RANKL-induced phosphorylation of ERK in primary mouse bone marrow macrophages without affecting other MAPK or NF-κB pathway proteins; meanwhile, it blocks H2O2-induced ERK activation at a concentration of 30 μM[3].
Myrislignan (30 μM; 60 min-7 days) inhibits osteoclastogenesis in primary mouse bone marrow macrophages by suppressing ERK phosphorylation and downstream protein expression; this effect is partially reversed by the ERK agonist LM22B-10 (HY-104047) at a concentration of 30 μM[3].
Myrislignan (32-70 mg/mL; 24 h) alters the gene expression of tachyzoites of the RH strain of Toxoplasma gondii; differentially expressed genes (DEGs) are enriched in redox processes and the oxidative phosphorylation pathway[4].
Myrislignan (32-70 mg/mL; 8-24 h) induces a statistically significant time-dependent increase in ROS activity in tachyzoites of the RH strain of Toxoplasma gondii[4].
Myrislignan (32-70 mg/mL) induces a statistically significant increase in SOD activity in tachyzoites of the RH strain of Toxoplasma gondii, but SOD levels do not increase over time[4].
Myrislignan (32-70 mg/mL; 16-24 h) induces the formation of autophagosome-like structures in tachyzoites of Toxoplasma gondii RH strain within infected Vero cells, followed by subsequent degeneration after treatment at 32 or 70 mg/mL for 16 or 24 h[4].
Myrislignan (32-70 mg/mL; 16 h) induces autophagosome formation in tachyzoites of the RH strain of Toxoplasma gondii[4].
Myrislignan (16-70 mg/mL; 16 h) upregulates the autophagy marker TgATG8-PE in a dose-dependent manner in tachyzoites of the RH strain of Toxoplasma gondii[4].
Myrislignan (32-70 mg/mL; 24 h) induces concentration-dependent cell death in tachyzoites of the RH strain of Toxoplasma gondii[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human gastric cancer SGC-7901 cells
-
Concentration:25; 50; 100; 200 μM
-
Incubation Time:48 h; 72 h
-
Result:Significantly inhibited SGC-7901 cell viability in a dose-dependent manner at 50, 100, and 200 μM after 48 h and 72 h.
Showed no significant difference in cell viability at 25 μM compared with control groups.
-
Cell Line:human gastric cancer SGC-7901 cells
-
Concentration:25; 50; 100; 200 μM
-
Incubation Time:48 h
-
Result:Increased the apoptosis rate of SGC-7901 cells, with a significant difference between the 200 μM group and the 100 μM group.
-
Cell Line:human gastric cancer SGC-7901 cells
-
Concentration:25; 50; 100; 200 μM
-
Incubation Time:48 h
-
Result:Downregulated the expression levels of PI3K and AKT proteins, and upregulated the expression levels of BAX, Caspase-3, and Caspase-9 proteins in a dose-dependent manner.
Showed relative PI3K expression of approximately 0.6, relative AKT expression of approximately 0.6, relative Caspase-9 expression of approximately 1.0, relative Caspase-3 expression of approximately 1.1, and relative BAX expression of approximately 1.1 at 200 μM.
-
Cell Line:human glioblastoma cell lines U87, U251; human low-grade glioma cell lines SHG44, HS683, SW1088; human normal astrocyte cell line NHA
-
Concentration:5, 10 and 15 μg/mL (U87); 10, 20 and 30 μg/mL (U251); 30, 40, 50 and 60 μg/mL (NHA)
-
Incubation Time:24 h, 48 h (U87, U251); null (NHA)
-
Result:Significantly inhibited the growth of U87 and U251 cells in a time- and dose-dependent manner.
Suppressed the growth of SHG44, HS683, and SW1088 cells.
Did not affect apoptosis or ferroptosis-associated protein levels in NHA cells at 30 μg/mL.
Inhibited NHA growth and caused lipid peroxidation at 40, 50, and 60 μg/mL.
-
Cell Line:human glioblastoma cell lines U87, U251
-
Concentration:5, 10 and 15 μg/mL (U87); 10, 20 and 30 μg/mL (U251)
-
Incubation Time:24 h
-
Result:Significantly reduced the number of migrated U87 and U251 cells in a dose-dependent manner.
Caused statistically significant decreases at all tested concentrations compared to untreated controls.
-
Cell Line:human glioblastoma cell lines U87, U251
-
Concentration:5, 10 and 15 μg/mL (U87); 10, 20 and 30 μg/mL (U251)
-
Incubation Time:48 h
-
Result:Significantly reduced the wound healing percentage of U87 and U251 cells in a dose-dependent manner.
Caused statistically significant decreases at all tested concentrations compared to untreated controls.
In Vivo
Myrislignan (15-30 mg/kg; i.p.; daily; 6 weeks) dose-dependently reduces ovariectomy-induced bone loss in female C57BL/6J mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nude mice (male, 5 weeks old, intracranial xenograft model via stereotactic implantation of U87 cells)[2]
-
Dosage:5 mg/kg
-
Administration:i.p.; every 3 days; 21 days
-
Result:Improved mouse survival compared to the control group.
Reduced tumor weight.
Decreased tumor tissue levels of phosphorylated p65 (p-p65), Slug, and SLC7A11.
Increased tumor tissue levels of E-cadherin.
-
Animal Model:C57BL/6J (11-weeks-old female; osteoporosis induced via bilateral ovariectomy)[3]
-
Dosage:15 mg/kg; 30 mg/kg
-
Administration:i.p.; daily; 6 weeks
-
Result:Increased bone volume/total volume (BV/TV) and trabecular number (Tb.N), and decreased trabecular separation (Tb.Sp) in the 30 mg/kg group compared to the ovariectomy-only group.
Showed intermediate improvements in BV/TV, Tb.N, and Tb.Sp in the 15 mg/kg group compared to the ovariectomy-only group.
Reduced bone surface/trabecular surface (BS/TS) and the number of TRAP-positive osteoclasts per trabecular surface (N.Oc/BS) in both dose groups compared to the ovariectomy-only group, with greater effects at 30 mg/kg.
Reduced the ratio of phosphorylated ERK (p-ERK) to total ERK in both dose groups compared to the ovariectomy-only group, with a more significant reduction at 30 mg/kg.
Chemical Information
-
CAS No. 171485-39-5
-
Appearance Solid
-
Molecular Weight 374.43
-
Formula C21H26O6
-
Color White to off-white
-
SMILES
C[C@@H]([C@@H](C1=CC(OC)=C(O)C=C1)O)OC(C(OC)=CC(CC=C)=C2)=C2OC
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (267.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.68 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.68 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Mitochondrial membrane-potential fluorescent assay
Mitochondrial membrane potential fluorescent assays estimate ΔΨm in living cells using lipophilic cationic dyes such as TMRM, TMRE, rhodamine 123, and JC-1, which accumulate in mitochondria according to membrane polarization; loss of signal after FCCP or CCCP treatment is interpreted as mitochondrial depolarization. TMRM/TMRE and rhodamine 123 are commonly used for semi-quantitative live-cell microscopy or flow cytometry, while JC-1 can report a shift from red aggregate fluorescence to green monomer fluorescence during depolarization; interpretation requires controls because dye concentration, quenching mode, cell type, dye efflux, and mitochondrial mass can affect fluorescence independently of ΔΨm.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Mitochondrial membrane-potential and mitochondrial mass staining
Mitochondrial membrane potential staining measures the electrochemical polarization across the mitochondrial inner membrane in live cells using lipophilic cationic fluorescent probes; early rhodamine-based work showed that selective mitochondrial dye accumulation is lost when the mitochondrial transmembrane potential is dissipated. JC-1 reports mitochondrial polarization by shifting from green monomer fluorescence to red J-aggregate fluorescence as dye concentration increases within energized mitochondria; therefore, the red/green fluorescence ratio is used as a relative readout of mitochondrial membrane potential. TMRE or TMRM staining provides a single-channel relative readout because these cationic rhodamine esters accumulate in polarized mitochondria, and lower fluorescence indicates reduced mitochondrial polarization when acquisition and dye-loading conditions are controlled. Mitochondrial mass staining is commonly performed with MitoTracker Green FM or related MitoTracker dyes as
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Cell invasion
Cell invasion is the ability of cells to migrate from one area to another via the extracellular matrix. Cell invasion is the response of normal and cancer cells to chemical and mechanical stimuli. Before migrating to a new region, the extracellular matrix is degraded by proteases within the cell. Cell invasion often occurs during wound repair, vascularization and inflammation, abnormal tissue invasion, and tumor cell metastasis.
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
Purity & Documentation
-
Data Sheet (298 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1].
Zhou YJ, et al. Myrislignan Induces Apoptosis in Gastric Cancer Cell Line Through PI3K/AKT Signaling Pathway. Sichuan Da Xue Xue Bao Yi Xue Ban. 2023 Jan;54(1):136-141. Chinese.
[Content Brief]
[2]. Zhou Y, et al. NF-B Inhibitor Myrislignan Induces Ferroptosis of Glioblastoma Cells via Regulating Epithelial-Mesenchymal Transformation in a Slug-Dependent Manner. Oxidative medicine and cellular longevity. 2023;2023:7098313. [Content Brief]
[3]. Yang T, et al. Myrislignan targets extracellular signal-regulated kinase (ERK) and modulates mitochondrial function to dampen osteoclastogenesis and ovariectomy-induced osteoporosis. Journal of translational medicine. 2023 Nov 22;21(1):839. [Content Brief]
[4].
Zhang J, et al. Myrislignan Induces Redox Imbalance and Activates Autophagy in Toxoplasma gondii. Front Cell Infect Microbiol. 2021 Sep 3;11:730222.
[Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6707 mL | 13.3536 mL | 26.7073 mL | 66.7682 mL |
| 5 mM | 0.5341 mL | 2.6707 mL | 5.3415 mL | 13.3536 mL | |
| 10 mM | 0.2671 mL | 1.3354 mL | 2.6707 mL | 6.6768 mL | |
| 15 mM | 0.1780 mL | 0.8902 mL | 1.7805 mL | 4.4512 mL | |
| 20 mM | 0.1335 mL | 0.6677 mL | 1.3354 mL | 3.3384 mL | |
| 25 mM | 0.1068 mL | 0.5341 mL | 1.0683 mL | 2.6707 mL | |
| 30 mM | 0.0890 mL | 0.4451 mL | 0.8902 mL | 2.2256 mL | |
| 40 mM | 0.0668 mL | 0.3338 mL | 0.6677 mL | 1.6692 mL | |
| 50 mM | 0.0534 mL | 0.2671 mL | 0.5341 mL | 1.3354 mL | |
| 60 mM | 0.0445 mL | 0.2226 mL | 0.4451 mL | 1.1128 mL | |
| 80 mM | 0.0334 mL | 0.1669 mL | 0.3338 mL | 0.8346 mL | |
| 100 mM | 0.0267 mL | 0.1335 mL | 0.2671 mL | 0.6677 mL |